A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors.

The study will be conducted in 3 parts:

  • Part A: MPT-0118 dose-escalation
  • Part B: MPT-0118 dose-escalation in combination with pembrolizumab
  • Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab

Learn More